AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie vyalev (foscarbidopa/foslevodopa) — U.S. net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
167
Period ended Dec 31, 2025
Change on a year earlier
+16,600.0%
1 in FY2024
History
3 years
Since FY2023
Sources
1
Form 10-K (filed 2026-02-20)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vyalev (foscarbidopa/foslevodopa) — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 167 | +16,600.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 1 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-20) ↗ |
Cite this data
StockData. (2026). AbbVie Vyalev (foscarbidopa/foslevodopa) — U.S. net revenues ($M) ($M), annual FY2023–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/vyalev_us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.